Citation: | Zhang L,Wang XT,Chu WL.Advances on the research and treatment of autoimmune disease-related chronic wounds[J].Chin J Burns Wounds,2022,38(6):563-568.DOI: 10.3760/cma.j.cn501225-20220329-00101. |
[1] |
姚泽欣,付小兵,程飚. 慢性创面愈合新理念:姑息性创面治疗的研究进展[J]. 中华烧伤杂志, 2020, 36(8): 754-757. DOI: 10.3760/cma.j.cn501120-20190929-00388.
|
[2] |
PatilS, GsV, SarodeGS, et al. Exploring the role of immunotherapeutic drugs in autoimmune diseases: a comprehensive review[J]. J Oral Biol Craniofac Res, 2021,11(2):291-296. DOI: 10.1016/j.jobcr.2021.02.009.
|
[3] |
ShanmugamVK. Vasculitic diseases and prothrombotic states contributing to delayed healing in chronic wounds[J]. Curr Dermatol Rep, 2016,5(4):270-277. DOI: 10.1007/s13671-016-0157-2.
|
[4] |
FurerV, RondaanC, HeijstekM, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD[J]. RMD Open, 2019,5(2):e001041. DOI: 10.1136/rmdopen-2019-001041.
|
[5] |
ZielinskiMR, SystromDM, RoseNR. Fatigue, sleep, and autoimmune and related disorders[J]. Front Immunol, 2019,10:1827. DOI: 10.3389/fimmu.2019.01827.
|
[6] |
PetriM. Antiphospholipid syndrome[J]. Transl Res, 2020,225:70-81. DOI: 10.1016/j.trsl.2020.04.006.
|
[7] |
JozicI, VukelicS, StojadinovicO, et al. Stress signals, mediated by membranous glucocorticoid receptor, activate PLC/PKC/GSK-3β/β-catenin pathway to inhibit wound closure[J]. J Invest Dermatol, 2017,137(5):1144-1154. DOI: 10.1016/j.jid.2016.11.036.
|
[8] |
CarolinaE, KatoT, KhanhVC, et al. Glucocorticoid impaired the wound healing ability of endothelial progenitor cells by reducing the expression of CXCR4 in the PGE2 pathway[J]. Front Med (Lausanne), 2018,5:276. DOI: 10.3389/fmed.2018.00276.
|
[9] |
MeszarosK, PatocsA. Glucocorticoids influencing Wnt/β-catenin pathway; multiple sites, heterogeneous effects[J]. Molecules, 2020, 25(7):1489. DOI: 10.3390/molecules25071489.
|
[10] |
DixonWG, SuissaS, HudsonM. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses[J]. Arthritis Res Ther, 2011,13(4):R139. DOI: 10.1186/ar3453.
|
[11] |
CordtzRL, ZobbeK, HøjgaardP, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers[J]. Ann Rheum Dis, 2018,77(2):281-288. DOI: 10.1136/annrheumdis-2017-212339.
|
[12] |
KlementMR, PenroseCT, BalaA, et al. How do previous solid organ transplant recipients fare after primary total knee arthroplasty?[J]. J Arthroplasty, 2016,31(3):609-615.e1. DOI: 10.1016/j.arth.2015.10.007.
|
[13] |
MabilleC, DegboeY, ConstantinA, et al. Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha[J]. Joint Bone Spine, 2017,84(4):441-445. DOI: 10.1016/j.jbspin.2016.06.011.
|
[14] |
姜玉峰. 中国体表慢性难愈合创面流行病学研究[D].北京:中国人民解放军军医进修学院, 2011. |
[15] |
ShanmugamVK, AngraD, RahimiH, et al. Vasculitic and autoimmune wounds[J]. J Vasc Surg Venous Lymphat Disord, 2017,5(2):280-292. DOI: 10.1016/j.jvsv.2016.09.006.
|
[16] |
JebakumarAJ, UdayakumarPD, CrowsonCS, et al. Occurrence and effect of lower extremity ulcer in rheumatoid arthritis--a population-based study[J]. J Rheumatol, 2014,41(3):437-443. DOI: 10.3899/jrheum.130392.
|
[17] |
WienkeJ, DeakinCT, WedderburnLR, et al. Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools[J]. Front Immunol, 2018,9:2951. DOI: 10.3389/fimmu.2018.02951.
|
[18] |
RuaroB, BruniC, WadeB, et al. Laser speckle contrast analysis: functional evaluation of microvascular damage in connective tissue diseases. Is there evidence of correlations with organ involvement, such as pulmonary damage?[J]. Front Physiol, 2021,12:710298. DOI: 10.3389/fphys.2021.710298.
|
[19] |
LimYL, BohelayG, HanakawaS, et al. Autoimmune pemphigus: latest advances and emerging therapies[J]. Front Mol Biosci, 2021,8:808536. DOI: 10.3389/fmolb.2021.808536.
|
[20] |
LouF, SunY, XuZ, et al. Excessive polyamine generation in keratinocytes promotes self-RNA sensing by dendritic cells in psoriasis[J]. Immunity, 2020,53(1):204-216.e10. DOI: 10.1016/j.immuni.2020.06.004.
|
[21] |
ZhangLJ. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis[J]. Front Immunol, 2019,10:1440. DOI: 10.3389/fimmu.2019.01440.
|
[22] |
CampanatiA, MaraniA, MartinaE, et al. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches[J]. Biomedicines, 2021, 9(11):1511.DOI: 10.3390/biomedicines9111511.
|
[23] |
ShanmugamVK, DeMariaDM, AttingerCE. Lower extremity ulcers in rheumatoid arthritis: features and response to immunosuppression[J]. Clin Rheumatol, 2011,30(6):849-853. DOI: 10.1007/s10067-011-1710-9.
|
[24] |
BrownM, O'ReillyS. The immunopathogenesis of fibrosis in systemic sclerosis[J]. Clin Exp Immunol, 2019,195(3):310-321. DOI: 10.1111/cei.13238.
|
[25] |
GiuggioliD, ManfrediA, LumettiF, et al. Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature[J]. Autoimmun Rev, 2018,17(2):155-164. DOI: 10.1016/j.autrev.2017.11.020.
|
[26] |
YangSH, ChangC, LianZX. Polymyositis and dermatomyositis-challenges in diagnosis and management[J]. J Transl Autoimmun, 2019,2:100018. DOI: 10.1016/j.jtauto.2019.100018.
|
[27] |
ManuelRC, PilarBZ, RaphaèleS, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements[J]. Rheumatology (Oxford), 2017,56(7):1245. DOI: 10.1093/rheumatology/kex157.
|
[28] |
GoodmanSM, SpringerB, GuyattG, et al. 2017 American college of rheumatology/American association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty[J]. Arthritis Rheumatol, 2017,69(8):1538-1551. DOI: 10.1002/art.40149.
|
[29] |
Kowal-BieleckaO, FransenJ, AvouacJ, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017,76(8):1327-1339. DOI: 10.1136/annrheumdis-2016-209909.
|
[30] |
RozinAP, EgoziD, RamonY, et al. Large leg ulcers due to autoimmune diseases[J]. Med Sci Monit, 2011,17(1):CS1-7. DOI: 10.12659/msm.881308.
|
[31] |
StevensNE, CowinAJ, KopeckiZ. Skin barrier and autoimmunity-mechanisms and novel therapeutic approaches for autoimmune blistering diseases of the skin[J]. Front Immunol, 2019,10:1089. DOI: 10.3389/fimmu.2019.01089.
|
[32] |
MandelinJ, EklundKK, ReitamoS. Leg ulcers treated with topical tacrolimus in patients with rheumatoid arthritis[J]. Acta Derm Venereol, 2010,90(6):633-634. DOI: 10.2340/00015555-0973.
|
[33] |
StarnoniM, PappalardoM, SpinellaA, et al. Systemic sclerosis cutaneous expression: management of skin fibrosis and digital ulcers[J]. Ann Med Surg (Lond), 2021,71:102984. DOI: 10.1016/j.amsu.2021.102984.
|
[34] |
HayashidaK, YamakawaS. Topical odour management in burn patients[J/OL]. Burns Trauma, 2021,9:tkab025[2022-02-23]. https://pubmed.ncbi.nlm.nih.gov/34458382/. DOI: 10.1093/burnst/tkab025.
|
[35] |
谭谦, 徐晔. 慢性创面治疗的理论和策略[J].中华烧伤杂志,2020,36(9):798-802. DOI: 10.3760/cma.j.cn501120-20200728-00361.
|
[36] |
BattistiA, BraccioliniV, TerenziV, et al. Free flaps in head and neck reconstruction in patients affected by vasculitis: to risk or not to risk?[J]. Oral Oncol, 2019,90:145-146. DOI: 10.1016/j.oraloncology.2018.12.012.
|
[37] |
Morales-PerezMJ, Gallardo-CaleroI, Rivas-NicollsD, et al. Reconstruction of COVID-19 vasculitis-related thumb necrosis with a microsurgical free flap[J]. Microsurgery, 2021,41(4):393-395. DOI: 10.1002/micr.30719.
|
[38] |
ChihabyN, OrliaguetM, Le PottierL, et al. Treatment of Sjögren's syndrome with mesenchymal stem cells: a systematic review[J]. Int J Mol Sci, 2021, 22(19):10474. DOI: 10.3390/ijms221910474.
|
[39] |
HolzerU, van Royen-KerkhofA, van der TorreP, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis[J]. Scand J Rheumatol, 2010,39(1):88-92. DOI: 10.3109/03009740903096622.
|
[40] |
PignattiM, SpinellaA, CocchiaraE, et al. Autologous fat grafting for the oral and digital complications of systemic sclerosis: results of a prospective study[J]. Aesthetic Plast Surg, 2020,44(5):1820-1832. DOI: 10.1007/s00266-020-01848-2.
|
[41] |
MaioneF, CappellanoG, BellanM, et al. Chicken-or-egg question: which came first, extracellular vesicles or autoimmune diseases?[J]. J Leukoc Biol, 2020,108(2):601-616. DOI: 10.1002/JLB.3MR0120-232R.
|
[42] |
GriecoGE, FignaniD, FormichiC, et al. Extracellular vesicles in immune system regulation and type 1 diabetes: cell-to-cell communication mediators, disease biomarkers, and promising therapeutic tools[J]. Front Immunol, 2021,12:682948. DOI: 10.3389/fimmu.2021.682948.
|
[43] |
NarauskaitėD, VydmantaitėG, RusteikaitėJ, et al. Extracellular vesicles in skin wound healing[J]. Pharmaceuticals (Basel), 2021, 14(8):811. DOI: 10.3390/ph14080811.
|
[44] |
HuP, YangQ, WangQ, et al. Mesenchymal stromal cells-exosomes: a promising cell-free therapeutic tool for wound healing and cutaneous regeneration[J/OL]. Burns Trauma, 2019,7:38[2022-02-23]. https://pubmed.ncbi.nlm.nih.gov/31890717/. DOI: 10.1186/s41038-019-0178-8.
|
[45] |
JiaY, WeiY. Modulators of microRNA function in the immune system[J]. Int J Mol Sci, 2020,21(7):2357. DOI: 10.3390/ijms21072357.
|
[46] |
ZhangJ, TanH, CaoQ, et al. Meta-analysis of miRNA variants associated with susceptibility to autoimmune disease[J]. Dis Markers, 2021,2021:9978460. DOI: 10.1155/2021/9978460.
|
[47] |
LiL, ZuoX, LiuD, et al. The profiles of miRNAs and lncRNAs in peripheral blood neutrophils exosomes of diffuse cutaneous systemic sclerosis[J]. J Dermatol Sci, 2020,98(2):88-97. DOI: 10.1016/j.jdermsci.2020.02.009.
|
[48] |
ZgheibC, HiltonSA, DewberryLC, et al. Use of cerium oxide nanoparticles conjugated with microRNA-146a to correct the diabetic wound healing impairment[J]. J Am Coll Surg, 2019,228(1):107-115. DOI: 10.1016/j.jamcollsurg.2018.09.017.
|
[49] |
LiJ, WeiM, LiuX, et al. The progress, prospects, and challenges of the use of non-coding RNA for diabetic wounds[J]. Mol Ther Nucleic Acids, 2021,24:554-578. DOI: 10.1016/j.omtn.2021.03.015.
|
[50] |
ZhangS, ChengZ, WangY, et al. The risks of miRNA therapeutics: in a drug target perspective[J]. Drug Des Devel Ther, 2021,15:721-733. DOI: 10.2147/DDDT.S288859.
|
[51] |
LouD, LuoY, PangQ, et al. Gene-activated dermal equivalents to accelerate healing of diabetic chronic wounds by regulating inflammation and promoting angiogenesis[J]. Bioact Mater, 2020,5(3):667-679. DOI: 10.1016/j.bioactmat.2020.04.018.
|
[52] |
MuirePJ, ThompsonMA, ChristyRJ, et al. Advances in immunomodulation and immune engineering approaches to improve healing of extremity wounds[J]. Int J Mol Sci, 2022,23(8) :4074. DOI: 10.3390/ijms23084074.
|
[53] |
GaoS, LiY, XiaoD, et al. Tetrahedral framework nucleic acids induce immune tolerance and prevent the onset of type 1 diabetes[J]. Nano Lett, 2021,21(10):4437-4446. DOI: 10.1021/acs.nanolett.1c01131.
|
[54] |
MaW, ZhanY, ZhangY, et al. The biological applications of DNA nanomaterials: current challenges and future directions[J]. Signal Transduct Target Ther, 2021, 6(1): 351. DOI: 10.1038/s41392-021-00727-9.
|